Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2020-129
    NCT ID
    • NCT03741127
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase Not Applicable
    Trials without phases (for example, studies of devices or behavioral interventions)
    • NA
    Principal Investigator
    • Abhinav
      Deol, M.D.

      Oncology - Hematology, Oncology - Medical View Profile


    The primary objective of this study is to evaluate the long-term safety of P-BCMA-101.

    Secondary objectives of this study are to evaluate:
    • The persistence of anti-tumor effect of P-BCMA-101 and its relationship to persistence of P-BCMA-101 cells, BCMA tumor surface expression and circulating BCMA
    • The persistence of the P-BCMA-101 cells
    • Evaluate the safety and effect of rimiducid on P-BCMA-101- related adverse events (AEs) if indicated
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266